Dr. Siefker-Radtke on PD-L1 as a Biomarker in Bladder Cancer

Video

In Partnership With:

Arlene O. Siefker-Radtke, MD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, clinical co-leader, Bladder SPORE Executive Committee, discusses why researchers and physicians should reconsider the utility of PD-L1 as a biomarker for patients with bladder cancer.

Arlene O. Siefker-Radtke, MD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, clinical co-leader, Bladder SPORE Executive Committee, discusses why researchers and physicians should reconsider the utility of PD-L1 as a biomarker for patients with bladder cancer.

PD-L1 hasn’t been a good marker for patients with urothelial cancer, she explains. There have been hints in some clinical trials that the response rate might be improved when looking at the PD-L1 expression on the immune infiltrate in addition to PD-L1 expression on the tumor cell.

However, response rates in PD-L1—negative tumors are higher with immunotherapy than single-agent taxane. PD-L1 is a very dynamic biomarker, she says, adding that it can be upregulated in patients who have had chemotherapy, BCG when given intravesically, or treatment with a PD-L1 inhibitor. Researchers have not yet had concrete data showing not to consider checkpoint inhibition when PD-L1 is low, because some patients still respond to such treatment.

At the moment, Siefker-Radtke says that she cannot recommend PD-L1 expression as a must-have biomarker because patients who don’t have it may still have benefit, may still respond, and may even have long-term durable responses that improve their overall survival.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD